Coronavirus company news summary – Lilly signs a 26,0000 dose supply deal with Canada – Moderna finalises vaccine supply deal with the EC

25 November 2020 (Last Updated November 25th, 2020 09:08)

25 November 2020 

Independent biomedical research and treatment centre for life-threatening diseases City of Hope initiated a Phase I clinical trial of its investigational SARS-CoV-2 vaccine among healthy participants between the ages of 18 and 55 years with no prior SARS-CoV-2 infection.

Allero Therapeutics and Abbreos have announced a collaboration to clinically test the  latter’s novel OroMucosal ImmunoGlobulin (OMIG) that addresses medical conditions associated with lethal amounts of pro-inflammatory cytokines and chemokines. The first focus of the initiative is to treat patients who are likely to suffer from Covid-19-associated acute respiratory distress syndrome (ARDS), and if not treated, require intensive care and ventilation.

Eli Lilly has signed a $32.5m agreement with Canada to supply 26,000 doses of  its antibody drug bamlanivimab to treat Covid-19 patients. The treatment was developed by Canadian biotech company AbCellera and is expected to be supplied to Canada between December and February.

A European Union (EU) official confirmed that the European Commission has signed a vaccine supply deal with Moderna. Moderna’s mRNA-1273 vaccine candidate met its primary efficacy endpoint in a Phase III COVE study with 94.5% efficacy.